Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis

2015 2012 Kneeman, 2012, Secondary causes of nonalcoholic fatty liver disease, Therap Adv Gastroenterol, 5, 199, 10.1177/1756283X11430859 Lonardo, 2019, NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management, Int J Mol Sci, 20, 2841, 10.3390/ijms20112841 Hashimoto, 2013, Characteristics and diagnosis of NAFLD/NASH, JGH, 28, 64 Cotter, 2020, Nonalcoholic fatty liver disease 2020: the state of the disease, Gastroenterology, 158, 1851, 10.1053/j.gastro.2020.01.052 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034 Duseja, 2010, Nonalcoholic fatty liver disease in India – a lot done, yet more required!, Indian J Gastroenterol, 29, 217, 10.1007/s12664-010-0069-1 Farrell, 2012, NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications, Gut Liver, 6, 149, 10.5009/gnl.2012.6.2.149 Aron-Wisnewsky, 2020, Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?, Gastroenterology, 158, 1881, 10.1053/j.gastro.2020.01.049 Patel, 2016, Clinical presentation and patient evaluation in nonalcoholic fatty liver disease, Clin Liver Dis, 20, 277, 10.1016/j.cld.2015.10.006 Amarapurkar, 2006, Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis, Ann Hepatol, 5, 30, 10.1016/S1665-2681(19)32036-8 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 Paul, 2020, Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult, Egypt Liver Journal, 10, 37, 10.1186/s43066-020-00043-x Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 126, 113, 10.1053/j.gastro.2005.04.014 Swain, 2017, Biochemical profile of nonalcoholic fatty liver disease patients in eastern India with histopathological correlation, Indian J Clin Biochem, 32, 306, 10.1007/s12291-016-0612-7 Duseja, 2007, Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation, W J G, 13, 649 Madan, 2006, Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians, W J G, 12, 3400 Zhou, 2007, Prevalence of fatty liver disease and its risk factors in the population of South China, W J G, 13, 6419 Hu, 2012, Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units, BMC Gastroenterol, 12, 123, 10.1186/1471-230X-12-123 Grandison, 2012, Can NASH be diagnosed, graded, and staged noninvasively?, Clin Liver Dis, 16, 567, 10.1016/j.cld.2012.05.001 Angulo, 1999, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 30, 1356, 10.1002/hep.510300604 Sorbi, 1999, The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease, Am J Gastroenterol, 94, 1018, 10.1111/j.1572-0241.1999.01006.x Mostafa, 2020, Fatty liver disease: a practical approach, Arch Pathol Lab Med, 144, 62, 10.5858/arpa.2019-0341-RA Angulo, 2015, Fibrosis in nonalcoholic fatty liver disease: mechanisms and clinical implications, Semin Liver Dis, 35, 132, 10.1055/s-0035-1550065 Santiago-Rolón, 2015, A Comparison of brunt's criteria, the non-alcoholic fatty liver disease activity score (NAS), and a proposed NAS scoring that includes fibrosis in non-alcoholic fatty liver disease staging, Puert Rico Health Sci J, 34, 189-94 Chen, 2017, Effect of hepatic steatosis on the progression of chronic hepatitis B: a prospective cohort and in vitro study, Oncotarget, 8, 58601, 10.18632/oncotarget.17380 Wang, 2019, Hepatitis B virus infection is not associated with fatty liver disease: evidence from a cohort study and functional analysis, Mol Med Rep, 19, 320 Bano, 2016, Thyroid function and the risk of nonalcoholic fatty liver disease: the rotterdam study, J Clin Endocrinol Metab, 101, 3204, 10.1210/jc.2016-1300 Xu, 2012, Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study, J Hepatol, 57, 1153, 10.1016/j.jhep.2012.05.025 Kim, 2018, Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis, Clin Gastroenterol Hepatol, 16, 123, 10.1016/j.cgh.2017.08.014 2016, Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants, Lancet, 387, 1377, 10.1016/S0140-6736(16)30054-X Gan, 2008, Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease, Clin Sci, 114, 543, 10.1042/CS20070461 Allard, 2002, Other disease associations with non-alcoholic fatty liver disease (NAFLD), Best Pract Res Clin Gastroenterol, 16, 783, 10.1053/bega.2002.0330 Pessayre, 2001, Mitochondria in steatohepatitis, Semin Liver Dis, 21, 57, 10.1055/s-2001-12929 Langman, 2001, Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury, J Gastroenterol Hepatol, 16, 1395, 10.1046/j.1440-1746.2001.02644.x Sakthiswary, 2014, Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis, Sci World J, 2014, 823763, 10.1155/2014/823763 Rahimi, 2020, Glucocorticoid-induced fatty liver disease, Diabetes Metab Syndr Obes, 13, 1133, 10.2147/DMSO.S247379 Santos, 2018, Food-drug interaction: anabolic steroids aggravate hepatic lipotoxicity and nonalcoholic fatty liver disease induced by trans fatty acids, Food Chem Toxicol, 116, 360, 10.1016/j.fct.2018.04.056 Pan, 2016, Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients, J Formos Med Assoc, 115, 411, 10.1016/j.jfma.2015.05.006 Saukkonen, 2006, ATS (American thoracic society) hepatotoxicity of antituberculosis therapy subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 174, 935, 10.1164/rccm.200510-1666ST Crum-Cianflone, 2009, Nonalcoholic fatty liver disease among HIV-infected persons, J Acquir Immune Defic Syndr, 50, 464, 10.1097/QAI.0b013e318198a88a Mogahed, 2020, Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years, Eur J Pediatr, 179, 719, 10.1007/s00431-019-03551-0